Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "NextGen-O2k H2020 SME Phase 1"

From Bioblast
Line 2: Line 2:
:::: <big><big>A project in progress</big></big>
:::: <big><big>A project in progress</big></big>


== Tyrolean Government grant ==
== Horizon2020 SME Instrument ==
[[File:Sponsorlogo gefoerdert RGB.jpg|right|350px]]
[[File:Horizon2020 logo jpg.jpg|80px|Horizon2020 logo jpg.jpg]]
::::* The project '''NextGen-O2k''' is supported by the "'''Technologieförderungsprogramm - Tiroler Innovationsförderung'''" of the Tyrolean Government.
::::* NextGen-O2k has successfully reached and accomplished Phase 1 of the two-step Horizon2020 SME funding instrument.
::::* '''Project duration''': 2015-02-01 to 2017-01-31.
::::* '''Project duration''': 2018-02-01 to 2018-05-31.
::::* '''Partners''': [[About Oroboros]], [[Oroboros partners| WGT Elektronik]], [[Oroboros partners| software security networks]].
::::* Funding: '''€ 50,000'''.
::::* '''Application''': 2015-01-30; '''Granted''': 2015-03-24 (total budget € 350.000).
::::* Funding: '''€ 140,000''' plus a bonus of '''€ 5,000''' for the implementation of gender sensitive actions.




== NextGen-O2k publication ==


::::* Harrison DK, Fasching M, Fontana-Ayoub M, Gnaiger E (2015) Cytochrome redox states and respiratory control in mouse and beef heart mitochondria at steady-state levels of hypoxia. J Appl Physiol Aug 6:jap.00146.2015. doi: 10.1152/japplphysiol.00146.2015. - [[Harrison_2015_J_Appl_Physiol |»Bioblast link«]]
== Project Output ==
The aim of the Phase 1 project was to generate a feasibility study (including a market study and a financial forecast) for the development and market launch of the NextGen-O2k and the Q2k. The freedom-to-operate (FTO) analysis that was carried out in the course of the feasibility study resulted in the following statement:  


 
"FREEDOM-TO-OPERATE: After careful analysis of these patents identified through Patent Inspiration, we
== The fourth dimension of respiratory control ==
conclude that we have not found any patent that overlaps with NextGen-O2k innovative properties. The
 
combination of sensors used by us is absolutely unique and, moreover, there is no a single device that includes
::::# On the "line": one dimension is insufficient.
the Q-sensor for coenzyme Q redox state. Therefore, we have full freedom-to-operate."
::::# Coupling and pathway control are two necessarily connected dimensions defining the “area” of respiratory control.
::::# Adding kinetics (including substrate kinetics of O<sub>2</sub>, CHO, adenylates, P<sub>i</sub>, and flux-force kinetics) is the third dimension bringing “volume” into the picture of classical mitochondrial respiratory control.
::::# The NextGen-O2k on top of O2k-MultiSensor modules and the [[O2k-FluoRespirometer]] represent the fourth dimension of respiratory control, by adding analysis of functional variables (such as ROS production, mt-membrane potential, Ca<sup>2+</sup>, proton flux, cytochrome and NADH redox states, ATP production) to the measurement of O<sub>2</sub> and O<sub>2</sub>-flux in the same chamber.
 
 
== Development of the NextGen-O2k: a look inside ==
 
:::: Different stages of prototype development: The [[NextGen-O2k description|NextGen-O2k]] is becoming more and more packed with two spectrofluorometers, two spectrophotometers, light guides, Peltier temperatue control with new heat pipes, microelectronics.
 
<gallery mode=default perrow=2 widths="500px" heights="300px">
File:NextGen 1.JPG
File:NextGen_2.JPG
File:NextGen_4.JPG
File:NextGen_5.JPG
</gallery>

Revision as of 15:14, 7 August 2018

                



NextGen-O2k H2020 SME Phase 1

A project in progress

Horizon2020 SME Instrument

Horizon2020 logo jpg.jpg

  • NextGen-O2k has successfully reached and accomplished Phase 1 of the two-step Horizon2020 SME funding instrument.
  • Project duration: 2018-02-01 to 2018-05-31.
  • Funding: € 50,000.


Project Output

The aim of the Phase 1 project was to generate a feasibility study (including a market study and a financial forecast) for the development and market launch of the NextGen-O2k and the Q2k. The freedom-to-operate (FTO) analysis that was carried out in the course of the feasibility study resulted in the following statement:

"FREEDOM-TO-OPERATE: After careful analysis of these patents identified through Patent Inspiration, we conclude that we have not found any patent that overlaps with NextGen-O2k innovative properties. The combination of sensors used by us is absolutely unique and, moreover, there is no a single device that includes the Q-sensor for coenzyme Q redox state. Therefore, we have full freedom-to-operate."